Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 391-403

  Reinhold, William C ^a   Reimers, Mark A ^a   Maunakea, Alika K ^a   Kim, Sohyoung ^a   Lababidi, Samir ^a   Scherf, Uwe ^b   Shankavaram, Uma T ^a   Ziegler, Micah S ^a   Stewart, Claudia ^c   Kouros Mehr, Hosein ^a   Cui, Hengmi ^d   Dolginow, Douglas ^b   Scudiero, Dominic A ^c   Pommier, Yves G ^a   Munroe, David J ^c   Feinberg, Andrew P ^d   Weinstein, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Gene Logic Inc   (United States)

^c SAIC FREDERICK INC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; GLYCOPROTEIN; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; EPITHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION;

BASE SEQUENCE; CADHERINS; CELL LINE, TUMOR; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 33847405772     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0609     Document Type: Article

References (61)

1. Overduin M, Harvey T, Bagby S, et al. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science 1995;267:386-9.
2. Wijnhoven B, Pignatelli M. E-cadherin-catenin: more than a "sticky" molecular complex. Lancet 1999;354:356-7.
3. Berx G, Cleton-Jansen A, Nollet F, at al. E-cadherin is a tumour/ invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14:6107-15.
4. Christofori G, Semb H. The role of the cell-adhesion molecule Ecadherin as a tumour-suppressor gene. Trends Biochem Sci 1999;24: 73-6.
5. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001;7:594-9.
6. Nass S, Herman J, Gabrielson E, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000;60: 4346-8.
7. Paul R, Ewing C, Jarrard D, Isaacs W. The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 1997;79 Suppi 1:37-43.
8. Li L, Zhao H, Nakajima K, et al. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 2001;166: 705-9.
9. Nojima D, Nakajima K, Li L, et al. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog 2001; 32:19-27.
10. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A 1995;92:7416-9.
11. Siitonen S, Kononen J, Helin H, Rantala I, Holli K, Isola J. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1996; 105:394-402.
12. Dunsmuir W, Gillett C, Meyer L, et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000;86:869-78.
13. Richards F, McKee S, Rajpar M, at al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8:607-10
14. Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003; 106:208-15.
15. Li L, Chui R, Sasaki M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000;60:873-6.
16. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart I. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-8.
17. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-37.
18. Hiraguri S, Godfrey T, Nakamura H, et al. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res 1998;58:1972-7.
19. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/ HDAC2 complex. Mol Cell Biol 2004;24:306-19.
20. Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 1995; 11:475-84.
21. Ribeiro-Filho L, Franks J, Sasaki M, et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 2002;34:187-98.
22. Feinberg A, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
23. Grady W, Willis J, Guilford P, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000;26:16-7.
24. Berx G, Staes K, van Hengel J, at al. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 1995; 26:281-9.
25. Esteller M, Corn P, Baylin S, Herman J. A Gene Hypermethylation Profile of Human Cancer. Cancer Res 2001;61:3225-9.
26. Kawakami T, Okamoto K, Ogawa O, Okada Y. Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. Urology 2003;61:226-30.
27. Herlyn M, Barking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res 2000; 10:303-12.
28. Hsu M, Andl T, Li G, Meinkoth J, Herlyn M. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000;113:1535-42.
29. Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding β-catenin signaling. Exp Cell Res 2004;297:142-51.
30. McGary E, Lev D, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
31. Paull K, Shoemaker R, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989; 81:1088-92.
32. Boyd M. Status of the NCI preclinical antitumor drug discovery screen. In Cancer: principles and practice of oncology update. Vol. 3. Philadelphia: J.B. Lippincott; 1989.
33. Weinstein J, Myers T, O'Connor P, at al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275: 343-9.
34. Myers T, Anderson N, Waltham M, at al. A protein expression database for the molecular pharmacology of cancer. Electrophoresis 1997; 18:647-53.
35. Roschke A, Tonon G, Gehlhaus K, at al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47.
36. Scherf U, Ross D, Waltham M, at al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
37. Stinson S, Alley M, Kopp W, at al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992;12:1035-53.
38. Holbeck S. Update on NCI in vitro drug screen utilities. Eur J Cancer 2004;40:785-93.
39. Weinstein J. Integromic Analysis of the NCI-60 Cancer, Cell Lines. Breast Dis 2004; 19:11-22.
40. Izquierdo M, Shoemaker R, Flens M, at al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996;65:230-7.
41. Weinstein J. Spotlight on molecular profiling: 'integromic, analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 2006;5:2601-5.
42. Lorenzi P, Reinhold W, Rudelius M, at al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006; 5:2613-23.
43. Ikediobi O, Davies H, Bignell G, at al. Mutation analysis of twenty-four known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5: 2606-12.
44. Corn P, Smith B, Ruckdeschel E, Douglas D, Baylin S, Herman J. Ecadherin expression is silenced by 5-pm CpG island methylation in acute leukemia. Clin Cancer Res 2000;6:4243-8.
45. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997;272:22322-9.
46. Sellappan S, Grijalva R, Zhou X, at al. Lineage infidelity of MDA-MB435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004;64:3479-85.
47. Ross D, Scherf U, Eisen M, at al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24: 227-35.
48. Staunton J, Slonim D, Coller H, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
49. Szakacs G, Annereau J, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37.
50. Huang Y, Anderle P, Bussey K, at al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301.
51. Annereau J, Szakacs G, Tucker CJ, at al. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 2004;66:1397-405.
52. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI60 cancer cell lines using new high-density 'reverse-phase' lysate microarrays. Proc Natl Aced Sci U S A 2003; 100: 14229-34.
53. Nishizuka S, Chen S, Gwadry F, at al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003;63:5243-50.
54. Ellison G, Klinowska T, Westwood R, Docter E, French T, Fox J. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002;55:294-9.
55. Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67.
56. Rakyan V, Hildmann T, Novik K, at al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLos Biol 2004;2:e405.
57. Clark S, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002;21:5380-7.
58. Stirzaker C, Song J, Davidson B, Clark S. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004;64: 3871-7.
59. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000;275:2727-32.
60. Esteller M, Garcia-Foncillas J, Andion E, at al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Mad 2000;343:1350-4.
61. Weinstein J. Pharmacogenomics-teaching old drugs new tricks. N Engl J Mad 2000;343:1350-4.